a:head aims to develop new therapeutics for the treatment of brain disorders based on human cerebral organoids
R&D:a:head’s drug discovery approach is based on human cerebral organoids, a revolutionary, paradigm-shifting new technology that allows the generation of mini brains from human stem cells in vitro. They capture the essential aspects of human embryonic brain development including brain patterning, formation of brain ventricles, differentiation into the various neuronal and supportive cell types and their correct three-dimensional arrangement.
Dr.-Bohr-Gasse 7, VBC6
1030 Wien
Vienna
Contact: Oliver Szolar (CEO)
Email: office@aheadbio.com
Website